DLDiede L. Loopik

Diede L. Loopik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Diede L. Loopik has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel high-resolution targeted sequencing of the cervicovaginal microbiome

    by Karolina M. Andralojc, Mariano A. Molina, Mengjie Qiu, Bram Spruijtenburg, Menno Rasing, Bernard Pater, Martijn A. Huynen, Bas E. Dutilh, Thomas H. A. Ederveen, Duaa Elmelik, et al.

    Background: The cervicovaginal microbiome (CVM) plays a significant role in women’s cervical health and disease. Microbial alterations at the species level and characteristic community state types (CST) have been associated with acquisition and persistence of high-risk human papillomavirus (hrHPV) infections that may result in progression of cervical lesions to malignancy. Current sequencing methods, especially most commonly used multiplex 16S rRNA gene sequencing, struggle to fully clarify these changes because they generally fail to provide sufficient taxonomic resolution to adequately perform species-level associative studies. To improve CVM species designation, we designed a novel sequencing tool targeting microbes at the species taxonomic rank and examined its potential for profiling the CVM. Results: We introduce an accessible and practical circular probe-based RNA sequencing (CiRNAseq) technology with the potential to profile and quantify the CVM. In vitro and in silico validations demonstrate that CiRNAseq can distinctively detect species in a mock mixed microbial environment, with the output data reflecting its ability to estimate microbes’ abundance. Moreover, compared to 16S rRNA gene sequencing, CiRNAseq provides equivalent results but with improved sequencing sensitivity. Analyses of a cohort of cervical smears from hrHPV-negative women versus hrHPV-positive women with high-grade cervical intraepithelial neoplasia confirmed known differences in CST occurring in the CVM of women with hrHPV-induced lesions. The technique also revealed variations in microbial diversity and abundance in the CVM of hrHPV-positive women when compared to hrHPV-negative women. Conclusions: CiRNAseq is a promising tool for studying the interplay between the CVM and hrHPV in cervical carcinogenesis. This technology could provide a better understanding of cervicovaginal CST and microbial species during health and disease, prompting the discovery of biomarkers, additional to hrHPV, that can help detect high-grade cervical lesions.


  • Open Access

    Cervical intraepithelial neoplasia and the risk of spontaneous preterm birth: A Dutch population-based cohort study with 45,259 pregnancy outcomes

    by Diede L. Loopik, Joris van Drongelen, Ruud L. M. Bekkers, Quirinus J. M. Voorham, Willem J. G. Melchers, Leon F. A. G. Massuger, Folkert J. van Kemenade, Albert G. Siebers

    Background: Excisional procedures of cervical intraepithelial neoplasia (CIN) may increase the risk of preterm birth. It is unknown whether this increased risk is due to the excision procedure itself, to the underlying CIN, or to secondary risk factors that are associated with both preterm birth and CIN. The aim of this study is to assess the risk of spontaneous preterm birth in women with treated and untreated CIN and examine possible associations by making a distinction between the excised volume of cervical tissue and having cervical disease.Methods and findings: This Dutch population-based observational cohort study identified women aged 29 to 41 years with CIN between 2005 and 2015 from the Dutch pathology registry (PALGA) and frequency matched them with a control group without any cervical abnormality based on age at and year of pathology outcome (i.e., CIN or normal cytology) and urbanization (P< 0.001). For women with treated CIN, these odds 2.07 times increased compared to the control group (95% CI 1.85 to 2.33;P< 0.001). Treated women had a 1.51 times increased odds of preterm birth compared to women with untreated CIN (95% CI 1.29 to 1.76;P< 0.001). Independent from cervical disease, a volume excised from the cervix of 0.5 to 0.9 cc increased the odds of preterm birth 2.20 times (37/379 versus 1,002/20,969; 95% CI 1.52 to 3.20;P< 0.001). These odds further increased 3.13 times and 5.93 times for women with an excised volume of 4 to 8.9 cc (90/724 versus 1,002/20,969; 95% CI 2.44 to 4.01;P< 0.001) and ≥9 cc (30/139 versus 1,002/20,969; 95% CI 3.86 to 9.13;P< 0.001), respectively. Limitations of the study include the retrospective nature, lack of sufficient information to calculate odds of preterm birth <24 weeks, and that the excised volume could only be calculated for a select group of women.Conclusions: In this study, we observed a strong correlation between preterm birth and a volume of ≥0.5 cc excised cervical tissue, regardless of the severity of CIN. Caution should be taken when performing excisional treatment in women of reproductive age as well as prudence in case of multiple biopsies. Fertile women with a history of performing multiple biopsies or excisional treatment for CIN may benefit from close surveillance during pregnancy.


  • Top Cited Papers

    The Natural History of Cervical Intraepithelial Neoplasia Grades 1, 2, and 3: A Systematic Review and Meta-analysis

    by Diede L. Loopik, Heidi A. Bentley, Maria N. MsC Eijgenraam, Joanna IntHout, Ruud L. M. Bekkers, James R. MB Bentley

    Objective: The aim of the study was to obtain an updated overview of regression, persistence, and progression rates of conservatively managed cervical intraepithelial neoplasia grade 1 (CIN 1)/CIN 2/CIN 3. Methods: Data sources were MEDLINE, Embase, and Cochrane (January 1, 1973–April 14, 2020). Two reviewers extracted data and assessed risk of bias. To estimate outcome rates, we pooled proportions of the individual study results using random-effects meta-analysis, resulting in point estimates and corresponding 95% CIs. Heterogeneity was quantified by the I 2 and τ2 measures. Results: Eighty-nine studies were included, 63 studies on CIN 1 (n = 6,080–8,767), 42 on CIN 2 (n = 2,909–3,830), and 7 on CIN 3 (n = 245–351). The overall regression, persistence, and progression to CIN 2 or worse and CIN 3 or worse rates for women with conservatively managed CIN 1 were 60% (95% CI = 55–65, I 2 = 92%), 25% (95% CI = 20–30, I 2 = 94%), 11% (95% CI = 8–13, I 2 = 89%), and 2% (95% CI = 1–3, I 2 = 82%), respectively. The overall regression, persistence, and progression rates for CIN 2 were 55% (95% CI = 50–60, I 2 = 85%), 23% (95% CI = 19–28, I 2 = 83%), and 19% (95% CI = 15–23, I 2 = 88%), respectively. Finally, for CIN 3, these were 28% (95% CI = 17–41, I 2 = 68%), 67% (95% CI = 36–91, I 2 = 84%), and 2% (95% CI = 0–25, I 2 = 95%), respectively. Cervical intraepithelial neoplasia grade 2 regression was significantly higher in women 30 years or younger and high-risk human papillomavirus–negative women (66%, 95% CI = 62–70, I 2 = 76%; 94%, 95% CI = 84–99, I 2 = 60%). Only 2/7,180 (0.03%) and 10/3,037 (0.3%) of the CIN 1 and CIN 2 cases progressed to cervical cancer. Conclusions: Most CIN 1/CIN 2 will regress spontaneously in less than 24 months, with the highest rates in high-risk human papillomavirus–negative and young women, whereas progression to cancer is less than 0.5%. Conservative management should be considered, especially in fertile women and with expected high compliance. Given the heterogeneity in regression rates of high-grade histology, this should be classified as CIN 2 or CIN 3 to guide management.


  • Open Access

    Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program

    by Diede L. Loopik, Lisanne M. Koenjer, Albert G. Siebers, Willem J.G. Melchers, Ruud L.M. Bekkers


  • Open Access

    Authors' reply re: Reflex cytology for triage of high-risk human-papillomavirus-positive self-sampled material in cervical cancer screening: a prospective cohort study

    by Diede L Loopik, Willem Jg Melchers, Judith Em Vedder, Adriaan Jc van Den Brule, Leon Fag Massuger, Ruud Lm Bekkers, Albert G Siebers

  • Open Access

    Reflex cytology for triage of high‐risk human papillomavirus positive self‐sampled material in cervical cancer screening: a prospective cohort study

    by Diede L Loopik, Willem Jg Melchers, Judith Em Vedder, Adriaan Jc van Den Brule, Leon Fag Massuger, Ruud Lm Bekkers, Albert G Siebers

    Objective HrHPV‐positive women detected with self‐sampling require an extra visit at the general practitioner for additional cytology testing, but the loss to follow‐up within this triage is substantial. The aim of this study was to evaluate the clinical utility of reflex cytology on hrHPV‐positive self‐samples for immediate stratification of women who need referral for colposcopy. Design A prospective cohort study. Setting Two Dutch cervical cancer screening laboratories. Population 1,014 screenees who tested hrHPV‐positive on self‐samples between 1/12/2018‐1/8/2019. Methods Self‐samples were directly used for cytological analysis. Cytological and histological outcomes during follow‐up were obtained from the Dutch Pathology Registry (PALGA). Main outcome measures Test performance of reflex cytology on self‐samples was determined for different thresholds and compared with physician‐taken cytology and histological outcomes. Results Reflex cytology on self‐samples for detecting abnormal cytology showed a sensitivity of 26.4% (95%CI 21.8‐31.3) and specificity of 90.5% (95%CI 87.7‐92.8). Of all ≥CIN2 cases, 29.4% (95%CI 22.5‐37.1) was detected with reflex cytology on self‐samples. The positive predictive value for detection of ≥CIN2 was higher with cytology on self‐collected samples than on physician‐collected samples. Of women who were lost to follow‐up, 12.9% were found to have abnormal cytology on their self‐sampled material. Conclusion Cytology testing is achievable on hrHPV‐positive self‐samples, could decrease the loss to follow‐up in screening and is easily implementable in the current clinical practice. Of all hrHPV‐positive women with abnormal cytology on additional physician‐collected samples, 26.4% could have been directly referred for colposcopy if triage with reflex cytology on self‐sampled material was performed.


  • Open Access

    The risk of cervical cancer after cervical intraepithelial neoplasia grade 3: A population-based cohort study with 80,442 women

    by Diede L. Loopik, Joanna IntHout, Renée M.F. Ebisch, Willem J.G. Melchers, Leon F.A.G. Massuger, Albert G. Siebers, Ruud L.M. Bekkers


  • Open Access

    Clinical practice variation and overtreatment risk in women with abnormal cervical cytology in the Netherlands: two-step versus see-and-treat approach

    by Diede L. Loopik, Albert G. Siebers, Willem J.G. Melchers, Leon F.A.G. Massuger, Ruud L.M. Bekkers


  • Open Access

    Oral contraceptive and intrauterine device use and the risk of cervical intraepithelial neoplasia grade III or worse: a population-based study

    by Diede L. Loopik, Joanna IntHout, Willem J.G. Melchers, Leon F.A.G. Massuger, Ruud L.M. Bekkers, Albert G. Siebers


  • Open Access

    The relative risk of noncervical high‐risk human papillomavirus‐related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population‐based study

    by Diede L. Loopik, Renée M. Ebisch, Joanna IntHout, Willem J. Melchers, Leon F. Massuger, Ruud L. Bekkers, Albert G. Siebers

    Women with cervical intraepithelial neoplasia grade 3 (CIN3) have a long‐lasting increased risk for noncervical high‐risk human papillomavirus (hrHPV)‐related (pre)malignancies. The aim of our study was to estimate this risk in women with recurrent CIN3 compared to women without a history of CIN3 and women with a single episode of CIN3. Women with a CIN3 diagnosis between 1990 and 2010 were obtained from the Dutch Pathology Registry (PALGA) and matched with a control group of women without CIN3. Analysis has been conducted in a subset of women with recurrent CIN3, defined as reoccurrence minimally 2 years post‐treatment. Cases of noncervical hrHPV‐related (pre)malignancies of the anus, vulva, vagina and oropharynx were identified until 2015 and incidence rate ratios (IRRs) were estimated. Then, 1,797 women with recurrent CIN3 were included with a median age of 34 years (range 18–76) and 31,594 person‐years of follow‐up. Women with recurrent CIN3 had an increased risk of developing noncervical hrHPV‐related (pre)malignancies compared to women without CIN3 with an IRR of 25.96 (95%CI 6.32–106.58). The IRR was 2.48 (95% CI 1.87–3.30) compared to women with a single episode of CIN3. Studies on posttreatment follow‐up and prophylactic hrHPV vaccination are warranted.